{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:15:11Z","timestamp":1787501711496,"version":"build-2736575974"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40257-019-00439-5","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:28:43Z","timestamp":1559035723000},"page":"625-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Biologic Treatment for Hidradenitis Suppurativa"],"prefix":"10.1007","volume":"20","author":[{"given":"Kelsey S.","family":"Flood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"439_CR1","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/j.1572-0241.2002.05950.x","volume":"97","author":"KH Katsanos","year":"2002","unstructured":"Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn\u2019s disease patient. Am J Gastroenterol. 2002;97:2155\u20136.","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"439_CR2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2133.2011.10698.x","volume":"166","author":"HH Van Der Zee","year":"2012","unstructured":"Van Der Zee HH, Laman JD, De Ruiter L, Dik WA, Prens EP. Adalimumab (antitumour necrosis factor-\u03b1) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166(2):298\u2013305.","journal-title":"Br J Dermatol"},{"key":"439_CR3","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","volume":"164","author":"HH van der Zee","year":"2011","unstructured":"van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2. Br J Dermatol. 2011;164:1292\u20138.","journal-title":"Br J Dermatol."},{"key":"439_CR4","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","volume":"76","author":"\u0141 Matusiak","year":"2017","unstructured":"Matusiak \u0141, Szcz\u0119ch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76:670\u20135.","journal-title":"J Am Acad Dermatol."},{"key":"439_CR5","first-page":"729","volume-title":"Dermatologic surg princ pract","author":"H Hurley","year":"1989","unstructured":"Hurley H. Axillary hyperhidrosis, aprocine bromhidrosis, hidradenitis suppurativa, and familia benign pemphigus: surgical approach. In: Roenigk R, Roenigk H, editors. Dermatologic Surgery Principles and Practice. New York: Marcel Dekker, Inc.; 1989. pp. 729\u201339."},{"key":"439_CR6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2340\/00015555-2513","volume":"97","author":"B Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th B, Janse I, Blok J, Driessen R, Boer J, Mekkes J, et al. Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group. Acta Derm Venereol. 2017;97:412\u20133.","journal-title":"Acta Derm Venereol."},{"issue":"3","key":"439_CR7","first-page":"156","volume":"99","author":"ML Porter","year":"2017","unstructured":"Porter ML, Kimball AB. Hidradenitis suppurativa scoring systems: can we choose just one? Cutis. 2017;99(3):156\u20137.","journal-title":"Cutis"},{"key":"439_CR8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","volume":"161","author":"K Sartorius","year":"2009","unstructured":"Sartorius K, Emtestam L, Jemec GBE, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831\u20139.","journal-title":"Br J Dermatol."},{"issue":"6","key":"439_CR9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Jemec GBE, Yang M, Kageleiry A, Signorovitch JE, Okun MM, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434\u201342.","journal-title":"Br J Dermatol"},{"key":"439_CR10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/ijd.IJD_412_16","volume":"63","author":"S Patil","year":"2018","unstructured":"Patil S, Apurwa A, Nadkarni N, Agarwal S, Chaudhari P, Gautam M. Hidradenitis Suppurativa: inside and out. Indian J Dermatol. 2018;63:91\u20138.","journal-title":"Indian J Dermatol."},{"issue":"12","key":"439_CR11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa. Ann Intern Med. 2012;157(12):846\u201355.","journal-title":"Ann Intern Med."},{"key":"439_CR12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30:989\u201394.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"439_CR13","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/jdv.15163","volume":"32","author":"AB Kimball","year":"2018","unstructured":"Kimball AB, Ganguli A, Fleischer A. Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018;32:2254\u20136.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"439_CR14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177:1401\u20139.","journal-title":"Br J Dermatol."},{"issue":"10","key":"439_CR15","first-page":"258","volume":"27","author":"A Chiricozzi","year":"2015","unstructured":"Chiricozzi A, Faleri S, Franceschini C, Caro RDC, Chimenti S, Bianchi L. AISI: A new disease severity assessment tool for hidradenitis suppurativa. Wounds. 2015;27(10):258\u201364.","journal-title":"Wounds."},{"issue":"3","key":"439_CR16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","volume":"158","author":"EJ Giamarellos-Bourboulis","year":"2007","unstructured":"Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2007;158(3):567\u201372.","journal-title":"Br J Dermatol."},{"issue":"1","key":"439_CR17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","volume":"152","author":"V Tzanetakou","year":"2016","unstructured":"Tzanetakou V, Kanni T, Giatrakou S, Katoulis A, Papadavid E, Netea MG, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52\u20139.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"439_CR18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamadermatol.2018.0141","volume":"154","author":"R Thomi","year":"2018","unstructured":"Thomi R, Cazzaniga S, Morteza Seyed Jafari S, Schlapbach C, Hunger RE. Association of hidradenitis suppurativa with T helper 1\/T helper 17 phenotypes a semantic map analysis. JAMA Dermatol. 2018;154(5):592\u20135.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"439_CR19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1365-2133.2011.10765.x","volume":"166","author":"VU Emelianov","year":"2012","unstructured":"Emelianov VU, Bechara FG, Gl\u00e4ser R, Langan EA, Taungjaruwinai WM, Schr\u00f6der JM, et al. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa\/acne inversa. Br J Dermatol. 2012;166(5):1023\u201334.","journal-title":"Br J Dermatol"},{"key":"439_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2340\/00015555-0749","volume":"89","author":"L Matusiak","year":"2009","unstructured":"Matusiak L, Bieniek A, Szepietowski J. Increased serum tumour necrosis factor- in hidradenitis suppurativa patients: Is there a basis for treatment with anti-tumour necrosis factor-agents? Acta Derm Venereol. 2009;89:601\u20133. https:\/\/doi.org\/10.2340\/00015555-0749 .","journal-title":"Acta Derm Venereol."},{"issue":"2","key":"439_CR21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archdermatol.2011.315","volume":"148","author":"B Dr\u00e9no","year":"2012","unstructured":"Dr\u00e9no B, Khammari A, Brocard A, Moyse D, Blouin E, Guillet G, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148(2):182\u20136.","journal-title":"Arch Dermatol"},{"issue":"4","key":"439_CR22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5021\/ad.2012.24.4.393","volume":"24","author":"FG Bechara","year":"2012","unstructured":"Bechara FG, Sand M, Skrygan M, Kreuter A, Altmeyer P, Gambichler T. Acne inversa: evaluating antimicrobial peptides and proteins. Ann Dermatol. 2012;24(4):393\u20137.","journal-title":"Ann Dermatol."},{"issue":"4","key":"439_CR23","doi-asserted-by":"publisher","first-page":"e0195325","DOI":"10.1371\/journal.pone.0195325","volume":"13","author":"M Liu","year":"2018","unstructured":"Liu M, Degner J, Davis JW, Idler KB, Nader A, Mostafa NM, et al. Identification of HLA-DRB1 association to adalimumab immunogenicity. PLoS One. 2018;13(4):e0195325. https:\/\/doi.org\/10.1371\/journal.pone.0195325 .","journal-title":"PLoS One."},{"key":"439_CR24","unstructured":"Adalimumab [package insert]. North Chicago, IL: Abbvie; 2018."},{"issue":"10","key":"439_CR25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","volume":"12","author":"CC Zouboulis","year":"2016","unstructured":"Zouboulis CC. Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa. Expert Rev Clin Immunol. 2016;12(10):1015\u201326.","journal-title":"Expert Rev Clin Immunol."},{"issue":"8","key":"439_CR26","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1365-4632.2010.04545.x","volume":"49","author":"M Amano","year":"2010","unstructured":"Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49(8):950\u20135.","journal-title":"Int J Dermatol."},{"issue":"2","key":"439_CR27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","volume":"165","author":"I Miller","year":"2011","unstructured":"Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GBE. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391\u20138.","journal-title":"Br J Dermatol."},{"issue":"5","key":"439_CR28","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bjd.14418","volume":"174","author":"JR Ingram","year":"2016","unstructured":"Ingram JR, Woo PN, Chua SL, Ormerod AD, Desai N, Kai AC, Hood K, Burton T, Kerdel F, Garner SE, Piguet V. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174(5):970\u20138.","journal-title":"Br J Dermatol."},{"issue":"3","key":"439_CR29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40257-017-0341-6","volume":"19","author":"C Ryan","year":"2018","unstructured":"Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, et al. Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis. Am J Clin Dermatol. 2018;19(3):437\u201347.","journal-title":"Am J Clin Dermatol."},{"issue":"5","key":"439_CR30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"6","key":"439_CR31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2018.05.015","volume":"79","author":"AB Kimball","year":"2018","unstructured":"Kimball AB, Sundaram M, Shields AL, Hudgens S, Okun M, Foley C, et al. Adalimumab alleviates skin pain in patients with moderate to severe hidradenitis suppurativa: secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. J Am Acad Dermatol. 2018;79(6):1141\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"439_CR32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60\u201369.e2.","journal-title":"J Am Acad Dermatol."},{"key":"439_CR33","unstructured":"Infliximab [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2018."},{"issue":"2","key":"439_CR34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205\u201317.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"439_CR35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2133.2007.08332.x","volume":"158","author":"JR Mekkes","year":"2008","unstructured":"Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158(2):370\u20134.","journal-title":"Br J Dermatol."},{"issue":"4","key":"439_CR36","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2006.07.027","volume":"56","author":"L Fardet","year":"2007","unstructured":"Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56(4):624\u20138.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"439_CR37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/09546634.2012.683767","volume":"23","author":"S Paradela","year":"2012","unstructured":"Paradela S, Rodr\u00edguez-Lojo R, Fern\u00e1ndez-Torres R, Ar\u00e9valo P, Fonseca E. Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat. 2012;23(4):278\u201383.","journal-title":"J Dermatolog Treat."},{"issue":"1","key":"439_CR38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2340\/00015555-0989","volume":"91","author":"A Brunasso","year":"2011","unstructured":"Brunasso A, Massone C. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: an update on infliximab. Acta Derm Venereol. 2011;91(1):70\u20131.","journal-title":"Acta Derm Venereol."},{"key":"439_CR39","unstructured":"Etanercept [package insert]. 2012. Thousands Oaks, CA: Amgen; 2012."},{"key":"439_CR40","doi-asserted-by":"publisher","first-page":"CD010081","DOI":"10.1002\/14651858.CD010081.pub2.","volume":"10","author":"JR Ingram","year":"2015","unstructured":"Ingram JR, Woo P-N, Chua SL, Ormerod AD, Desai N, Kai AC, et al. Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev. 2015;10:CD010081. https:\/\/doi.org\/10.1002\/14651858.CD010081.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"439_CR41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/09546634.2017.1395806","volume":"29","author":"M Maarouf","year":"2018","unstructured":"Maarouf M, Clark AK, Lee DE, Shi VY. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018;29(5):441\u20139.","journal-title":"J Dermatolog Treat."},{"issue":"2","key":"439_CR42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-015-0516-5","volume":"76","author":"IE Deckers","year":"2016","unstructured":"Deckers IE, Prens EP. An update on medical treatment options for hidradenitis suppurativa. Drugs. 2016;76(2):215\u201329.","journal-title":"Drugs."},{"issue":"4","key":"439_CR43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anplas.2017.03.012","volume":"62","author":"E Robert","year":"2017","unstructured":"Robert E, Bodin F, Paul C, Konstantinou M-P, Gall Y, Grolleau J-L, et al. Non-surgical treatments for hidradenitis suppurativa: a systematic review. Ann Chir Plast Esth\u00e9tique. 2017;62(4):274\u201394.","journal-title":"Ann Chir Plast Esth\u00e9tique."},{"issue":"5","key":"439_CR44","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","volume":"146","author":"DR Adams","year":"2010","unstructured":"Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146(5):501\u20134.","journal-title":"Arch Dermatol."},{"issue":"4","key":"439_CR45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","volume":"60","author":"RA Lee","year":"2009","unstructured":"Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60(4):565\u201373.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"439_CR46","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1600-0625.2009.00967.x","volume":"19","author":"A Pelekanou","year":"2010","unstructured":"Pelekanou A, Kanni T, Savva A, Mouktaroudi M, Raftogiannis M, Kotsaki A, et al. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial. Exp Dermatol. 2010;19(6):538\u201340.","journal-title":"Exp Dermatol."},{"issue":"4","key":"439_CR47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","volume":"154","author":"C Cusack","year":"2006","unstructured":"Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154(4):726\u20139.","journal-title":"Br J Dermatol."},{"key":"439_CR48","unstructured":"Golimumab [package insert]. Horsham, PA: Janssen Biotech Inc.; 2011."},{"issue":"12","key":"439_CR49","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.dld.2016.09.010","volume":"48","author":"A Tursi","year":"2016","unstructured":"Tursi A. Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab. Dig Liver Dis. 2016;48(12):1511\u20132.","journal-title":"Dig Liver Dis."},{"issue":"2","key":"439_CR50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000343221","volume":"226","author":"HH van der Zee","year":"2013","unstructured":"van der Zee HH, Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology. 2013;226(2):97\u2013100.","journal-title":"Dermatology."},{"key":"439_CR51","unstructured":"Cimzia (certolizumab pegol) [Package insert]. Smyrna, GA: UCB, Inc.; 2016."},{"issue":"3","key":"439_CR52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.12788\/j.sder.2018.042","volume":"37","author":"ML Porter","year":"2018","unstructured":"Porter ML, Golbari NM, Lockwood SJ, Kimball AB. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. Semin Cutan Med Surg. 2018;37(3):182\u20139.","journal-title":"Semin Cutan Med Surg."},{"issue":"3","key":"439_CR53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/dth.12222","volume":"28","author":"FL Sand","year":"2015","unstructured":"Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015;28(3):158\u201365.","journal-title":"Dermatol Ther."},{"issue":"2","key":"439_CR54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjd.17036","volume":"180","author":"ZZN Yiu","year":"2019","unstructured":"Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, et al. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the UK and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2019;180(2):329\u201337.","journal-title":"Br J Dermatol."},{"issue":"9","key":"439_CR55","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of serious infection with biologic and systemic treatment of psoriasis. JAMA Dermatol. 2015;151(9):961\u20139.","journal-title":"JAMA Dermatol."},{"issue":"6","key":"439_CR56","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","volume":"64","author":"ED Dommasch","year":"2011","unstructured":"Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035\u201350.","journal-title":"J Am Acad Dermatol."},{"key":"439_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3899\/jrheum.140104","volume":"91","author":"L Pescitelli","year":"2014","unstructured":"Pescitelli L, Ricceri F, Prignano F. Tuberculosis reactivation risk in dermatology. J Rheumatol Suppl. 2014;91:65\u201370. https:\/\/doi.org\/10.3899\/jrheum.140104 .","journal-title":"J Rheumatol Suppl."},{"key":"439_CR58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3899\/jrheum.140102","volume":"91","author":"F Cantini","year":"2014","unstructured":"Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47\u201355. https:\/\/doi.org\/10.3899\/jrheum.140102 .","journal-title":"J Rheumatol Suppl."},{"issue":"9","key":"439_CR59","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","volume":"167","author":"KL Wood","year":"2003","unstructured":"Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-\u03b1 therapy. Am J Respir Crit Care Med. 2003;167(9):1279\u201382.","journal-title":"Am J Respir Crit Care Med."},{"issue":"5","key":"439_CR60","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.smj.0000242797.49218.44","volume":"100","author":"M Dweik","year":"2007","unstructured":"Dweik M, Baethge BA, Duarte AG. Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab. South Med J. 2007;100(5):517\u20138.","journal-title":"South Med J."},{"issue":"6","key":"439_CR61","first-page":"730","volume":"137","author":"J Lapins","year":"2001","unstructured":"Lapins J, Ye W, Nyr\u00e9n O, Emtestam L. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol. 2001;137(6):730\u20134.","journal-title":"Arch Dermatol."},{"issue":"2","key":"439_CR62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/iwj.12671","volume":"14","author":"N Jourabchi","year":"2017","unstructured":"Jourabchi N, Fischer AH, Cimino-Mathews A, Waters KM, Okoye GA. Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J. 2017;14(2):435\u20138.","journal-title":"Int Wound J."},{"issue":"2","key":"439_CR63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clindermatol.2016.10.019","volume":"35","author":"G Fabbrocini","year":"2017","unstructured":"Fabbrocini G, Ruocco E, De Vita V, Monfrecola G. Squamous cell carcinoma arising in long-standing hidradenitis suppurativa: an overlooked facet of the immunocompromised district. Clin Dermatol. 2017;35(2):225\u20137.","journal-title":"Clin Dermatol."},{"issue":"2","key":"439_CR64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000269836","volume":"220","author":"C Lavogiez","year":"2010","unstructured":"Lavogiez C, Delaporte E, Darras-Vercambre S, Martin De Lassalle E, Castillo C, Mirabel X, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010;220(2):147\u201353.","journal-title":"Dermatology."},{"issue":"6","key":"439_CR65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jdcr.2017.08.017","volume":"3","author":"R Giesey","year":"2017","unstructured":"Giesey R, Delost GR, Honaker J, Korman NJ. Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa. JAAD Case Rep. 2017;3(6):489\u201391.","journal-title":"JAAD Case Rep."},{"key":"439_CR66","doi-asserted-by":"crossref","unstructured":"Scheinfeld N. A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma. Dermatol Online J. 2014;20(3). https:\/\/escholarship.org\/uc\/item\/4hz964w9 .","DOI":"10.5070\/D3203021764"},{"issue":"2","key":"439_CR67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","volume":"20","author":"J Askling","year":"2011","unstructured":"Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20(2):119\u201330.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"439_CR68","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","volume":"70","author":"X Mariette","year":"2011","unstructured":"Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895\u2013904.","journal-title":"Ann Rheum Dis."},{"key":"439_CR69","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/09546634.2011.652064","volume":"23","author":"F Kamangar","year":"2012","unstructured":"Kamangar F, Neuhaus IM, Koo JYM. An evidence-based review of skin cancer rates on biologic therapies. J Dermatolog Treat. 2012;23(4):305\u201315.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"439_CR70","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00054725-199905000-00008","volume":"5","author":"WJ Sandborn","year":"1999","unstructured":"Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5(2):119\u201333.","journal-title":"Inflamm Bowel Dis."},{"issue":"Suppl 5","key":"439_CR71","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","volume":"51","author":"A Rubbert-Roth","year":"2012","unstructured":"Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology. 2012;51(Suppl 5):v38\u201347. https:\/\/doi.org\/10.1093\/rheumatology\/kes114 .","journal-title":"Rheumatology."},{"issue":"4","key":"439_CR72","first-page":"241","volume":"29","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29(4):241\u201358.","journal-title":"A systematic review and meta-analysis. BioDrugs."},{"issue":"3","key":"439_CR73","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/09546630801955143","volume":"19","author":"N Scheinfeld","year":"2008","unstructured":"Scheinfeld N. Menorrhagia and severe menstrual pain related to the use of adalimumab in a psoriatic. J Dermatolog Treat. 2008;19(3):188\u20139.","journal-title":"J Dermatolog Treat."},{"issue":"7","key":"439_CR74","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00296-010-1455-9","volume":"32","author":"C Bes","year":"2012","unstructured":"Bes C, Soy M. Serious menstrual bleeding associated with use of TNF alpha blocker: two cases. Rheumatol Int. 2012;32(7):2175\u20136.","journal-title":"Rheumatol Int."},{"issue":"4","key":"439_CR75","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"439_CR76","unstructured":"Ustekinumab [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2018."},{"issue":"4","key":"439_CR77","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","volume":"174","author":"JL Blok","year":"2016","unstructured":"Blok JL, Li K, Brodmerkel C, Horv\u00e1tovich P, Jonkman MF, Horv\u00e1th B. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839\u201346.","journal-title":"Br J Dermatol."},{"issue":"7","key":"439_CR78","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","volume":"26","author":"WP Gulliver","year":"2012","unstructured":"Gulliver WP, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26(7):911\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"439_CR79","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ad.2013.09.011","volume":"105","author":"MI Santos-P\u00e9rez","year":"2014","unstructured":"Santos-P\u00e9rez MI, Garc\u00eda-Rodicio S, Del Olmo-Revuelto MA, Pozo-Rom\u00e1n T. Ustekinumab for hidradenitis suppurativa: a case report. Actas Dermosifiliogr. 2014;105(7):720\u20132.","journal-title":"Actas Dermosifiliogr."},{"issue":"4","key":"439_CR80","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","volume":"72","author":"EM Baerveldt","year":"2013","unstructured":"Baerveldt EM, Kappen JH, Thio HB, Van Laar JAM, Martin Van Hagen P, Prens EP. Successful long-term triple disease control by ustekinumab in a patient with Beh\u00e7et\u2019s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72(4):626\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"439_CR81","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136\u201344.","journal-title":"N Engl J Med."},{"key":"439_CR82","unstructured":"Guselkumab [package insert]. Horsham, PA: Janssen Biotech Inc.; 2017.\u00a0"},{"key":"439_CR83","unstructured":"A study to evaluate the efficacy, safety and tolerability of guselkumab for the treatment of participants with moderate to severe hidradenitis suppurativa (HS) (NOVA). Identifier NCT03628924. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03628924?cond=hidradenitis+suppurativa&rank=13 . Accessed 06 May 2019.\u00a0"},{"key":"439_CR84","unstructured":"Risankizumab [package insert]. North Chicago, IL: AbbVie Inc.; 2019."},{"key":"439_CR85","unstructured":"A global study comparing risankizumab to placebo in adult participants with moderate to serve hidradenitis suppurativa. Identifier: NCT03926169. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03926169?cond=hidradenitis+suppurativa&rank=6 . Accessed 06 May 2019."},{"issue":"7","key":"439_CR86","first-page":"706","volume":"14","author":"K Papp","year":"2015","unstructured":"Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706\u201314.","journal-title":"J Drugs Dermatol."},{"issue":"3","key":"439_CR87","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1001-9294(14)60057-2","volume":"29","author":"Y Liu","year":"2014","unstructured":"Liu Y, Gong J, Li W. Therapeutic effect and safety of ustekinumab for plaque psoriasis: a meta-analysis. Chin Med Sci J. 2014;29(3):131\u20138.","journal-title":"Chin Med Sci J."},{"key":"439_CR88","unstructured":"Secukinumab [package insert]. East Hanover, NJ: Novartis; 2015."},{"issue":"4","key":"439_CR89","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5021\/ad.2018.30.4.462","volume":"30","author":"P Giuseppe","year":"2018","unstructured":"Giuseppe P, Nicola P, Valentina C, Elena C, Salvatrice C, Rosario G, et al. A case of moderate hidradenitis suppurativa and psoriasis treated with secukinumab. Ann Dermatol. 2018;30(4):462\u20134.","journal-title":"Ann Dermatol."},{"issue":"1","key":"439_CR90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2340\/00015555-2794","volume":"98","author":"A Schuch","year":"2018","unstructured":"Schuch A, Fischer T, Boehner A, Biedermann T, Volz T. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Derm Venereol. 2018;98(1):151\u20132.","journal-title":"Acta Derm Venereol."},{"key":"439_CR91","doi-asserted-by":"publisher","first-page":"8685136","DOI":"10.1155\/2018\/8685136","volume":"2018","author":"A-HR J\u00f8rgensen","year":"2018","unstructured":"J\u00f8rgensen A-HR, Yao Y, Thomsen SF. Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep Dermatol Med. 2018;2018:8685136. https:\/\/doi.org\/10.1155\/2018\/8685136 .","journal-title":"Case Rep Dermatol Med."},{"issue":"1","key":"439_CR92","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bjd.15769","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182\u20135.","journal-title":"Br J Dermatol."},{"key":"439_CR93","unstructured":"Exploratory trial evaluating cosentyx (secukinumab) for patients with moderate-to-severe hidradenitis suppurativa. Identifier NCT03099980. 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03099980?cond=Hidradenitis+Suppurativa&draw=1&rank=17 . Accessed 06 May 2019."},{"key":"439_CR94","unstructured":"Jancin B. Secukinumab shows promise in hidradenitis suppurativa. In: MDedge. 2018. https:\/\/www.mdedge.com\/internalmedicine\/article\/183857\/medical-dermatology\/secukinumab-shows-promise-hidradenitis ."},{"key":"439_CR95","unstructured":"This is a study of efficacy and safety of two secukinumab dose regimens in subjects with moderate to severe hidradenitis suppurativa (HS). (SUNSHINE). Identifier NCT03713619. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03713619?cond=Hidradenitis+Suppurativa&rank=13 . Accessed 06 May 2019.\u00a0"},{"key":"439_CR96","unstructured":"Study of efficacy and safety of two secukinumab dose regimens in subjects with moderate to severe hidradenitis suppurativa (HS) (SUNRISE). Identifier NCT03713632. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03713632?cond=Hidradenitis+Suppurativa&rank=12 .\u00a0Accessed 06 May 2019."},{"key":"439_CR97","unstructured":"A study to test the efficacy, safety and pharmacokinetics of bimekizumab in subjects with moderate to severe hidradenitis suppurativa. Identifier NCT03248531. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03248531?cond=Hidradenitis+Suppurativa&draw=1&rank=9 .\u00a0Accessed 06 May 2019."},{"issue":"5","key":"439_CR98","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","volume":"83","author":"S Glatt","year":"2017","unstructured":"Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991\u20131001.","journal-title":"Br J Clin Pharmacol."},{"key":"439_CR99","unstructured":"Efficacy, safety, and pharmacokinetic study of CJM112 in hidradenitis suppurativa patients. Identifier NCT02421172. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02421172?cond=Hidradenitis+Suppurativa&draw=1&rank=11 .\u00a0Accessed 06 May 2019.\u00a0"},{"key":"439_CR100","unstructured":"Brodalumab [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2017."},{"key":"439_CR101","unstructured":"Treatment of moderate hidradenitis suppurativa. Identifier NCT03910803. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03910803?cond=hidradenitis+suppurativa&rank=15 . Accessed 06 May 2019."},{"issue":"5","key":"439_CR102","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1060028015626545","volume":"50","author":"JY Ryoo","year":"2016","unstructured":"Ryoo JY, Yang HJ, Ji E, Yoo BK. Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis. Ann Pharmacother. 2016;50(5):341\u201351.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"439_CR103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","volume":"177","author":"DM Saunte","year":"2017","unstructured":"Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47\u201362.","journal-title":"Br J Dermatol."},{"key":"439_CR104","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2147\/TCRM.S79053","volume":"11","author":"M Roman","year":"2015","unstructured":"Roman M, Madkan VK, Chiu MW. Profile of secukinumab in the treatment of psoriasis: current perspectives. Ther Clin Risk Manag. 2015;11:1767\u201377. https:\/\/doi.org\/10.2147\/TCRM.S79053 .","journal-title":"Ther Clin Risk Manag."},{"issue":"3","key":"439_CR105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441\u20138.e2.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"439_CR106","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/bjd.13002","volume":"171","author":"HH van der Zee","year":"2014","unstructured":"van der Zee HH, de Winter K, van der Woude CJ, Prens EP. The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br J Dermatol. 2014;171(3):673\u20135.","journal-title":"Br J Dermatol."},{"issue":"5","key":"439_CR107","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jdcr.2016.07.009","volume":"2","author":"JM Thompson","year":"2016","unstructured":"Thompson JM, Cohen LM, Yang CS, Kroumpouzos G. Severe, ulcerative, lichenoid mucositis associated with secukinumab. JAAD Case Rep. 2016;2(5):384\u20136.","journal-title":"JAAD Case Rep."},{"issue":"4","key":"439_CR108","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1111\/1346-8138.13637","volume":"44","author":"T Komori","year":"2017","unstructured":"Komori T, Honda T, Endo Y, Kaku Y, Otsuka A, Kabashima K. Oral lichen planus associated with candidiasis during secukinumab treatment. J Dermatol. 2017;44(4):e60\u20131. https:\/\/doi.org\/10.1111\/1346-8138.13637 .","journal-title":"J Dermatol."},{"issue":"6","key":"439_CR109","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jdcr.2018.04.015","volume":"4","author":"TM Capusan","year":"2018","unstructured":"Capusan TM, Herrero-Moyano M, Mart\u00ednez-Mera CR, Freih-Fraih AW, Dauden E. Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event? JAAD Case Rep. 2018;4(6):521\u20133.","journal-title":"JAAD Case Rep"},{"issue":"6","key":"439_CR110","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaad.2014.07.048","volume":"71","author":"KB Gordon","year":"2014","unstructured":"Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71(6):1176\u201382.","journal-title":"J Am Acad Dermatol."},{"key":"439_CR111","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","volume":"136","author":"C Hotz","year":"2016","unstructured":"Hotz C, Boniotto M, Guguin A, Surenaud M, Jean-Louis F, Tisserand P, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol. 2016;136(9):1768\u201380.","journal-title":"J Invest Dermatol."},{"key":"439_CR112","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","volume":"149","author":"K Zarchi","year":"2013","unstructured":"Zarchi K, Dufour DN, Jemec GBE. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 2013;149:1192\u20134.","journal-title":"JAMA Dermatol."},{"key":"439_CR113","unstructured":"Anakinra [package insert]. Stockholm, Sweden: Sweidsh Orpham Biovitrum AB; 2018."},{"issue":"6","key":"439_CR114","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1111\/ijd.13528","volume":"56","author":"L Jennings","year":"2017","unstructured":"Jennings L, Molloy O, Quinlan C, Kelly G, O\u2019Kane M. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier. Int J Dermatol. 2017;56(6):e128\u20139. https:\/\/doi.org\/10.1111\/ijd.13528 .","journal-title":"Int J Dermatol."},{"issue":"2","key":"439_CR115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","volume":"70","author":"KS Leslie","year":"2014","unstructured":"Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(2):243\u201351.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"439_CR116","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bjd.13292","volume":"172","author":"D Menis","year":"2015","unstructured":"Menis D, Maro\u00f1as-Jim\u00e9nez L, Delgado-Marquez AM, Postigo-Llorente C, Vanaclocha-Sebasti\u00e1n F. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy. Br J Dermatol. 2015;172(3):810\u20131.","journal-title":"Br J Dermatol."},{"issue":"4","key":"439_CR117","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","volume":"138","author":"T Kanni","year":"2018","unstructured":"Kanni T, Argyropoulou M, Spyridopoulos T, Pistiki A, Stecher M, Dinarello CA, et al. MABp1 Targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol. 2018;138(4):795\u2013801.","journal-title":"J Invest Dermatol."},{"key":"439_CR118","unstructured":"A phase II study of Bermekimab (MABp1) in patients with moderate to severe atopic dermatitis. Identifier NCT03496974. 2018.\u00a0 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03496974 . Accessed 06 May 2019."},{"key":"439_CR119","unstructured":"MABp1 in hidradenitis suppurativa refractory to adalimumab. Identifier NCT02643654. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02643654?cond=hidradenitis+suppurativa . Accessed 06 May 2019."},{"key":"439_CR120","unstructured":"A study of Bermekimab in patients with hidradenitis suppurativa. Identifier NCT03512275. 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03512275?cond=Hidradenitis+Suppurativa&rank=2 . Accessed 06 May 2019.\u00a0"},{"key":"439_CR121","unstructured":"Assessment of the safety, tolerability and efficacy of MEDI8968 in subjects with moderate to severe hidradenitis suppurativa. Identifier NCT01838499. 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01838499?cond=hidradenitis+suppurativa . Accessed 06 May 2019."},{"issue":"7","key":"439_CR122","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","volume":"17","author":"J Ram\u00edrez","year":"2018","unstructured":"Ram\u00edrez J, Ca\u00f1ete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018;17(7):727\u201332.","journal-title":"Expert Opin Drug Saf."},{"issue":"8","key":"439_CR123","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","volume":"37","author":"J Sota","year":"2018","unstructured":"Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018;37(8):2233\u201340.","journal-title":"Clin Rheumatol."},{"issue":"8","key":"439_CR124","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00296-018-4041-1","volume":"38","author":"S Nikfar","year":"2018","unstructured":"Nikfar S, Saiyarsarai P, Tigabu BM, Abdollahi M. Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int. 2018;38(8):1363\u201383.","journal-title":"Rheumatol Int."},{"key":"439_CR125","unstructured":"Efalizumab. South San Francisco: Genentech Inc. Raptiva; 2019.\u00a0"},{"issue":"6","key":"439_CR126","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2007.07.032","volume":"57","author":"BE Strober","year":"2007","unstructured":"Strober BE, Kim C, Siu K. Efalizumab for the treatment of refractory hidradenitis suppurativa. J Am Acad Dermatol. 2007;57(6):1090\u20131.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"439_CR127","first-page":"712","volume":"13","author":"EF Prater","year":"2014","unstructured":"Prater EF, Day A, Patel M, Menter A. A retrospective analysis of 72 patients on prior efalizumab subsequent to the time of voluntary market withdrawal in 2009. J Drugs Dermatol. 2014;13(6):712\u20138.","journal-title":"J Drugs Dermatol."},{"key":"439_CR128","first-page":"413","volume":"179","author":"T Kanni","year":"2018","unstructured":"Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br J Dermatol. 2018;179(2):413\u20139.","journal-title":"Br J Dermatol."},{"key":"439_CR129","unstructured":"Efficacy and safety study of IFX-1 in patients with moderate to severe hidradenitis suppurativa (HS) (SHINE). Identifier NCT03487276. 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03487276?cond=Hidradenitis+Suppurativa&draw=1&rank=26 . Accessed 06\u00a0 May 2019.\u00a0"},{"key":"439_CR130","unstructured":"Studying complement inhibition in patients with moderate to severe hidradenitis suppurativa. Identifier NCT03001622. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03001622?cond=hidradenitis+suppurativa&rank=15 . Accessed 06 May 2019.\u00a0"},{"key":"439_CR131","unstructured":"Guo R, Habel M, Zenker O, Giamarellos-Bourboulis, Evangelos Riedemann N. IFX-1 block the anaphylatoxin C5a\u2014an anti-inflammatory effect in patients with hidradenitis suppurativa. https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=2ahUKEwjWjbPsrYfiAhWuT98KHbYCDj4QFjABegQIABAC&url=https%3A%2F%2Fwww.inflarx.de%2Fdam%2Fjcr%3Aec982d1e-f82b-4992-a1b0-ff6e69a04b6b%2FGuo_2017_poster.pdf&usg=AOvVaw2M-FuvVuHcKLGcoYjmE31W . Accessed 06 May 2019."},{"issue":"1","key":"439_CR132","first-page":"192","volume":"166","author":"P Ulrich","year":"2018","unstructured":"Ulrich P, Flandre T, Espie P, Sickert D, Rubic-Schneider T, Shaw DA, et al. Nonclinical safety assessment of CFZ533, a Fc-silent anti-CD40 antibody, in cynomolgus monkeys. Toxicol Sci. 2018;166(1):192\u2013202.","journal-title":"Toxicol Sci."},{"issue":"12","key":"439_CR133","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","volume":"18","author":"J Ristov","year":"2018","unstructured":"Ristov J, Espie P, Ulrich P, Sickert D, Flandre T, Dimitrova M, et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant. 2018;18(12):2895\u2013904.","journal-title":"Am J Transplant."},{"issue":"27","key":"439_CR134","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1097\/MD0000000000000187","volume":"93","author":"AV Marzano","year":"2014","unstructured":"Marzano AV, Ceccherini I, Gattorno M, Fanoni D, Caroli F, Rusmini M, et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine. 2014;93(27):e187. https:\/\/doi.org\/10.1097\/MD0000000000000187 .","journal-title":"Medicine."},{"key":"439_CR135","unstructured":"Study of efficacy and safety of investigational treatments in patients with moderate to severe hidradenitis suppurativa. Identifier NCT03827798. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03827798?cond=hidradenitis+suppurativa&rank=3 . Accessed 06 May 2019.\u00a0"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00439-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00439-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00439-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:19:38Z","timestamp":1721315978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00439-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00439-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"28 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"ABK received honoraria as a consultant and grants as an investigator from Janssen, AbbVie, Eli Lilly, UCB, and Novartis, and has received fellowship funding from Janssen and Abbvie. MLP received funding for her fellowship from Abbvie and Jansen that went directly to her institution from 7\/1\/17 to 8\/31\/18.\u00a0MLP has received honoraria as a\u00a0consultant for Novartis and AbbVie. KSF received funding for her fellowship from Abbvie and Jansen that went directly to her institution from 7\/1\/18 through 6\/30\/19.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}